PPT Slide
Hadziyannis and colleagues [N. Engl. J. Med. 348, 800-807 (2003)] report the efficacy of 10 mg of adefovir daily as compared with placebo for 48 weeks in patients with chronic HBeAg-negative HBV infection.
In this study conducted at 32 sites world-wide, histologic abnormalities improved significantly in the adefovir dipivoxil group (with improvement in 64 percent of patients, as compared with 33 percent of those in the placebo group), HBV DNA levels became undetectable (in 51 percent of patients vs. 0 percent in the placebo group). The serum alanine aminotransferase level normalized (in 72 percent of patients vs. 29 percent in the placebo group). There was no evidence of renal toxicity.
Mailliard & Gollan, N. Engl. J. Med. 348, 848-850 (2003)
“Suppressing Hepatitis B without Resistance – So Far, So Good”